These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 12587965

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Localization of 28-kDa peroxiredoxin in rat epithelial tissues and its antioxidant properties.
    Novoselov SV, Peshenko IV, Popov VI, Novoselov VI, Bystrova MF, Evdokimov VJ, Kamzalov SS, Merkulova MI, Shuvaeva TM, Lipkin VM, Fesenko EE.
    Cell Tissue Res; 1999 Dec; 298(3):471-80. PubMed ID: 10639737
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma.
    Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, Soini Y.
    J Pathol; 2002 Mar; 196(3):316-23. PubMed ID: 11857495
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cyclophilin a binds to peroxiredoxins and activates its peroxidase activity.
    Lee SP, Hwang YS, Kim YJ, Kwon KS, Kim HJ, Kim K, Chae HZ.
    J Biol Chem; 2001 Aug 10; 276(32):29826-32. PubMed ID: 11390385
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Peroxiredoxins in breast carcinoma.
    Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL, Soini Y.
    Clin Cancer Res; 2003 Aug 15; 9(9):3418-24. PubMed ID: 12960131
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders.
    Krapfenbauer K, Engidawork E, Cairns N, Fountoulakis M, Lubec G.
    Brain Res; 2003 Mar 28; 967(1-2):152-60. PubMed ID: 12650976
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Nonredundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells.
    Shen C, Nathan C.
    Mol Med; 2002 Feb 28; 8(2):95-102. PubMed ID: 12080185
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Induction of peroxiredoxins in transplanted livers and demonstration of their in vitro cytoprotection activity.
    Shau H, Merino A, Chen L, Shih CC, Colquhoun SD.
    Antioxid Redox Signal; 2000 Feb 28; 2(2):347-54. PubMed ID: 11229538
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immunohistochemical demonstration of carbonic anhydrase isoenzyme VI (CA VI) expression in rat lower airways and lung.
    Leinonen JS, Saari KA, Seppänen JM, Myllylä HM, Rajaniemi HJ.
    J Histochem Cytochem; 2004 Aug 28; 52(8):1107-12. PubMed ID: 15258187
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins.
    Butterfield LH, Merino A, Golub SH, Shau H.
    Antioxid Redox Signal; 1999 Aug 28; 1(4):385-402. PubMed ID: 11233141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.